ArticleJournal of ovarian research2025
Determination of the optimal follicle size at the time of trigger in patients with diminished ovarian reserve undergoing ICSI cycle.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The estradiol-to-periovulatory follicle ratio (E2/N16) as a marker of follicular endocrine efficiency and embryological outcomes in ART cycles.Frontiers in endocrinology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with diminished ovarian reserve (DOR) typically have fewer retrieved oocytes and lower pregnancy rates than normal responders. Therefore, maximizing oocyte yield is particularly important to improve their reproductive outcomes.
aimThe purpose of this study was to improve reproductive outcomes in assisted reproductive technology (ART) by determining the optimal follicle size to induce final oocyte maturation in patients with DOR.
methodsA total of 430 follicles from 98 DOR patients were included in this study. Controlled ovarian stimulation was conducted by a GnRH antagonist protocol, with ovulation triggered when the leading follicle reached ≥ 17 mm, followed by oocyte retrieval 36 h later. On the day of oocyte retrieval, in the operating theatre, all follicles were carefully measured, one by one, by a second trained individual just before aspiration. Then, each follicle was aspirated separately and collected in a separate tube. Throughout the laboratory process, oocytes were tracked and managed based on the size of the follicle from which they originated. Based on follicle size, 11–14 mm, 15–17 mm, and ≥ 18 mm, the follicles were divided into three groups. Reproductive outcomes in this study were included Cumulus Oocyte Complex (COC) retrieval rate, metaphase II (MII) oocyte rate, fertilization rate, and top-quality embryo (TQE) rate.
resultsThe final analysis included a total of 430 follicles were measured and aspirated. Follicles measuring 15–17 mm exhibited a significantly higher COC retrieval rate (88.1%), MII oocyte rate (83.3%), fertilization rate (97.1%), and TQE rate (65.4%), in comparison to follicles measuring 11–14 mm and ≥ 18 mm (p < 0.05). The COC retrieval rate and the MII retrieval rate were 79.16% and 66.66%, for follicles measuring 14 mm, and were 45.09% and 33.33%, for follicles measuring 13 mm, respectively (p < 0.05). ROC analysis identified an optimal follicle size of 14.5–15.5 mm for COC retrieval. The incidence of premature ovulation was 13.27% and the mean size of the leading follicle on the day of trigger was 18.6 mm in patients with premature ovulation.
conclusionOur study suggests that oocyte retrieval, maturation and embryo development are optimized by triggering final oocyte maturation at a follicle size of 15–17 mm. In addition, there is a need to reconsider the standard trigger criteria in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.